Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 11, 2015

Ireland’s Mallinckrodt agrees to acquire immunotherapy firm Therakos for $1.3bn

Ireland-based Mallinckrodt has signed a definitive agreement with The Gores Group to acquire immunotherapy firm Therakos for $1.3bn.

Ireland-based Mallinckrodt has signed a definitive agreement with The Gores Group to acquire immunotherapy firm Therakos for $1.3bn.

The acquired business is anticipated to expand Mallinckrodt’s speciality brands portfolio and diversify its hospital offerings through the addition of a high-margin drug-device system, which is used in hospitals and major medical centres in 25 countries.

Therakos provides treatment platforms for immune disorders, including Cellex Photopheresis system, and also delivers autologous immune cell therapy through extracorporeal photopheresis (ECP).

"This transaction demonstrates our ongoing commitment to building a strong, highly profitable hospital growth business."

The photopheresis system secured approval from US Food and Drug Administration to treat skin manifestations of cutaneous T-cell lymphoma (CTCL) in persons who failed to respond to other forms of treatment.

Outside the US, the system obtained approval for ECP, allowing physicians to use it in different conditions including CTCL, graft versus host disease, Crohn’s disease, solid organ transplants and other diseases.

Mallinckrodt president Mark Trudeau said: "This transaction demonstrates our ongoing commitment to building a strong, highly profitable hospital growth business as we build and diversify Mallinckrodt’s speciality brands portfolio.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

"With this expansion into immunotherapy we add to our footprint of nuclear medicine, pain management and respiratory neonatal critical care, broadening our touch points in hospitals and further expanding our portfolio with innovative therapies."

Therakos photopheresis platforms, including the Cellex system, are expected to further expand Mallinckrodt’s presence from multimodal surgical pain management and critical care respiratory therapies in neonatal intensive care units.

It will include innovative therapies that harness the patient’s own immune systems to fight disease and improve health.

Following the acquisition, Therakos’s commercial team will be integrated into Mallinckrodt’s current critical care organisation within its hospital speciality brands business.

Subject to customary closing conditions, the transaction is expected to be completed during the third quarter of this year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU